HS
BEAM icon

HighVista Strategies’s Beam Therapeutics BEAM Stock Holding History

HighVista Strategies’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,584
Closed -$600K – 108
2022
Q3 		$600K Sell
12,584
-8,396
-40% -$479K 0.34% 76
2022
Q2 		$812K Buy
20,980
+9,878
+89% +$393K 0.49% 46
2022
Q1 		$636K Sell
11,102
-2,436
-18% -$160K 0.4% 64
2021
Q4 		$1.08M Buy
13,538
+2,064
+18% +$177K 0.86% 41
2021
Q3 		$998K Buy
+11,474
New +$1.15M 0.66% 53

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

HighVista Strategies's BEAM Position: Q4 2022 in Review

HighVista Strategies sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 12,584 shares — an estimated $600K sold.

HighVista Strategies first reported a position in BEAM in Q3 2021 and held it in 5 quarters. The position peaked at $1.08M in Q4 2021. 207 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • HighVista Strategies reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HighVista Strategies sold 12,584 Beam Therapeutics shares in Q4 2022, an estimated $600K.
  • HighVista Strategies first reported a position in Beam Therapeutics in Q3 2021 and held it in 5 quarters.
  • HighVista Strategies's Beam Therapeutics position peaked at $1.08M in Q4 2021.
  • 207 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on HighVista Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.